Mild cognitive impairment: the Manchester consensus

Dunne, Ross A, Aarsland, Dag, O'Brien, John T, Ballard, Clive, Banerjee, Sube, Fox, Nick C, Isaacs, Jeremy D, Underwood, Benjamin R, Perry, Richard J, Chan, Dennis, Dening, Tom, Thomas, Alan J, Schryer, Jeffrey, Jones, Anne-Marie, Evans, Alison R and others, (2021) Mild cognitive impairment: the Manchester consensus. Age and Ageing, 50 (1). pp. 72-80. ISSN 0002-0729

[img] PDF - Published Version
Available under License Creative Commons Attribution-Non-Commercial.

Download (179kB)

Abstract

Given considerable variation in diagnostic and therapeutic practice, there is a need for national guidance on the use of neuroimaging, fluid biomarkers, cognitive testing, follow-up and diagnostic terminology in Mild Cognitive Impairment (MCI). MCI is a heterogenous clinical syndrome reflecting a change in cognitive function and deficits on neuropsychological testing but relatively intact activities of daily living. MCI is a risk state for further cognitive and functional decline with 5- 15% of people developing dementia per year. However, 50% remain stable at 5 years and in a minority, symptoms resolve over time. There is considerable debate about whether MCI is a useful clinical diagnosis, or whether the use of the term prevents proper inquiry (by history, examination and investigations) into underlying causes of cognitive symptoms, which can include prodromal neurodegenerative disease, other physical or psychiatric illness, or combinations thereof. Cognitive testing, neuroimaging and fluid biomarkers can improve the sensitivity and specificity of aetiological diagnosis, with growing evidence that thesemay also help guide prognosis.Diagnostic criteria allow for a diagnosis of Alzheimer's disease to bemade where MCI is accompanied by appropriate biomarker changes, but in practice, such biomarkers are not available in routine clinical practice in the UK. This would change if disease-modifying therapies became available and required a definitive diagnosis but would present major challenges to the National Health Service and similar health systems. Significantly increased investment would be required in training, infrastructure and provision of fluid biomarkers and neuroimaging. Statistical techniques combining markers may provide greater sensitivity and specificity than any single diseasemarker but their practical usefulness will depend on large-scale studies to ensure ecological validity and that multiple measures, e.g. both cognitive tests and biomarkers, are widely available for clinical use. To perform such large studies, we must increase research participation amongst those with MCI.

Item Type: Article
Keywords: Alzheimer’s, CSF, Lewy body, amyloid, biomarkers, cerebrovascular, clinical trials, dementia, mild cognitive impairment, neurodegeneration, neuroimaging, neuropsychology, older people, risk reduction, tau, Activities of Daily Living, Alzheimer Disease, Amyloid beta-Peptides, Biomarkers, Cognitive Dysfunction, Consensus, Disease Progression, Humans, Neurodegenerative Diseases, Neuropsychological Tests, Peptide Fragments, State Medicine
Schools and Departments: Brighton and Sussex Medical School > Brighton and Sussex Medical School
SWORD Depositor: Mx Elements Account
Depositing User: Mx Elements Account
Date Deposited: 10 Sep 2021 12:41
Last Modified: 04 Oct 2021 16:49
URI: http://sro.sussex.ac.uk/id/eprint/101626

View download statistics for this item

📧 Request an update